Analyst Ratings for Esperion Therapeutics
Portfolio Pulse from Benzinga Insights
In the last 3 months, 12 analysts have offered 12-month price targets for Esperion Therapeutics (NASDAQ:ESPR), with an average price target of $12.88, up 21.74% from the previous average of $10.58. The company has received 8 bullish, 1 somewhat bullish, 2 indifferent, and 1 somewhat bearish ratings.
June 01, 2023 | 7:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Esperion Therapeutics has an average 12-month price target of $12.88, up 21.74% from the previous average, with mostly bullish analyst ratings.
The increase in the average price target and the predominantly bullish analyst ratings suggest a positive outlook for Esperion Therapeutics' stock price in the short term. The 21.74% increase in the average price target indicates that analysts have become more optimistic about the company's prospects, which could lead to an upward trend in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100